Clinically actionable information with a simple blood draw – The OncoBEAM™ RAS CRC KIT!

Go beyond KRAS – The All-RAS-Panel
Recent clinical studies have shown that the detection of additional mutations in KRAS and NRAS codons should also be considered in determining patient eligibility for targeted anti‐EGFR therapies. The OncoBEAM™ RAS qualitative digital PCR based test is intended for the detection of gene mutations in KRAS codons 12, 13, 59, 61, 117, 146 and NRAS codons 12, 13, 59, 61, 117, 146 extracted from Stage IV colorectal cancer patient plasma. The kit is intended to aid the clinician in determining potential benefit of anti-epidermal growth factor receptor (EGFR) therapy to colorectal cancer patients.


Visit Sysmex Inostics website to find out more about our BEAMING Technology:
Sysmex Inostics website



OncoBEAM™ RAS CRC Kit offers the following advantages:

  • High Concordance with Tissue OncoBEAM™ RAS CRC Kit demonstrated an overall percent agreement of 93.3 % with tissue
  • Safety and Convenience Minimally invasive, few risks
  • Accurate Information Blood sample evaluation represents current mutational status of patient’s disease; Information of tumor dynamics in real time
  • No Selection Bias Evaluate primary tumor and metastases with one sample
  • Ability to Monitor Allows multiple measurements to assess drug response and resistance
  • Time Sensitive Rapid turnaround time from biopsy to result
Add Enquiry
I agree that Sysmex will store and process the above information in order to evaluate my request and reply as set out in the Privacy Policy.*



Please help us to serve you better by sharing your experience.

Do you find the resources provided at this site useful?

What scientific topics you would be most interested to read?